Clinical study of T3/T4 laryngeal carcinoma

Mioko Matsuo, Fumihide Rikimaru, Yuichiro Higaki, Kichinobu Tomita

Research output: Contribution to journalArticle

Abstract

A total of 72 consecutive laryngeal carcinoma patients at stage T3 or T4 were studied. The laryngeal cancer patients were treated first with concurrent chemoradiotherapy (40 Gy) in our department. Patients with residual disease subsequently underwent curative surgery, and chemoradiotherapy was continued to 70 Gy for those without residual disease. The three-year disease-specific-free survival (DSS) rates in patients with supraglottic, glottic and subglottic tumors were 58%, 71% and 100%, respectively. In patients at stage T3/T4, the DSS rates were 75%/46%, and in those with/without lymph node metastasis (N+/N-) the rates were 56%/78%. The three-year laryngeal preservation (LP) rates in patients with supraglottic/glottic/subglottic tumors, T3/T4 and N+/N- tumors were 12%/26%/50%, 28%/4% and 13%/29%, respectively. The recurrence rate was 29%, of which 75% have died, primarily of distant metastasis. These DSS and LP rates were not significantly different among the three subregions and N stages, although those in patients at stage T4 were significantly low, compared with T3 patients (p=0.01). These results suggest that additional treatment may be required for patients with T4 disease. Chemotherapy after surgery is now considered for T4 patients.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalJapanese Journal of Head and Neck Cancer
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

Carcinoma
Disease-Free Survival
Chemoradiotherapy
Tongue
Survival Rate
Clinical Studies
Neoplasm Metastasis
Neoplasms
Laryngeal Neoplasms
Lymph Nodes
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Oncology

Cite this

Clinical study of T3/T4 laryngeal carcinoma. / Matsuo, Mioko; Rikimaru, Fumihide; Higaki, Yuichiro; Tomita, Kichinobu.

In: Japanese Journal of Head and Neck Cancer, Vol. 38, No. 1, 01.01.2012, p. 39-42.

Research output: Contribution to journalArticle

Matsuo, Mioko ; Rikimaru, Fumihide ; Higaki, Yuichiro ; Tomita, Kichinobu. / Clinical study of T3/T4 laryngeal carcinoma. In: Japanese Journal of Head and Neck Cancer. 2012 ; Vol. 38, No. 1. pp. 39-42.
@article{fa51d3ecfca94add9d158e8f73fcfe21,
title = "Clinical study of T3/T4 laryngeal carcinoma",
abstract = "A total of 72 consecutive laryngeal carcinoma patients at stage T3 or T4 were studied. The laryngeal cancer patients were treated first with concurrent chemoradiotherapy (40 Gy) in our department. Patients with residual disease subsequently underwent curative surgery, and chemoradiotherapy was continued to 70 Gy for those without residual disease. The three-year disease-specific-free survival (DSS) rates in patients with supraglottic, glottic and subglottic tumors were 58{\%}, 71{\%} and 100{\%}, respectively. In patients at stage T3/T4, the DSS rates were 75{\%}/46{\%}, and in those with/without lymph node metastasis (N+/N-) the rates were 56{\%}/78{\%}. The three-year laryngeal preservation (LP) rates in patients with supraglottic/glottic/subglottic tumors, T3/T4 and N+/N- tumors were 12{\%}/26{\%}/50{\%}, 28{\%}/4{\%} and 13{\%}/29{\%}, respectively. The recurrence rate was 29{\%}, of which 75{\%} have died, primarily of distant metastasis. These DSS and LP rates were not significantly different among the three subregions and N stages, although those in patients at stage T4 were significantly low, compared with T3 patients (p=0.01). These results suggest that additional treatment may be required for patients with T4 disease. Chemotherapy after surgery is now considered for T4 patients.",
author = "Mioko Matsuo and Fumihide Rikimaru and Yuichiro Higaki and Kichinobu Tomita",
year = "2012",
month = "1",
day = "1",
doi = "10.5981/jjhnc.38.39",
language = "English",
volume = "38",
pages = "39--42",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "1",

}

TY - JOUR

T1 - Clinical study of T3/T4 laryngeal carcinoma

AU - Matsuo, Mioko

AU - Rikimaru, Fumihide

AU - Higaki, Yuichiro

AU - Tomita, Kichinobu

PY - 2012/1/1

Y1 - 2012/1/1

N2 - A total of 72 consecutive laryngeal carcinoma patients at stage T3 or T4 were studied. The laryngeal cancer patients were treated first with concurrent chemoradiotherapy (40 Gy) in our department. Patients with residual disease subsequently underwent curative surgery, and chemoradiotherapy was continued to 70 Gy for those without residual disease. The three-year disease-specific-free survival (DSS) rates in patients with supraglottic, glottic and subglottic tumors were 58%, 71% and 100%, respectively. In patients at stage T3/T4, the DSS rates were 75%/46%, and in those with/without lymph node metastasis (N+/N-) the rates were 56%/78%. The three-year laryngeal preservation (LP) rates in patients with supraglottic/glottic/subglottic tumors, T3/T4 and N+/N- tumors were 12%/26%/50%, 28%/4% and 13%/29%, respectively. The recurrence rate was 29%, of which 75% have died, primarily of distant metastasis. These DSS and LP rates were not significantly different among the three subregions and N stages, although those in patients at stage T4 were significantly low, compared with T3 patients (p=0.01). These results suggest that additional treatment may be required for patients with T4 disease. Chemotherapy after surgery is now considered for T4 patients.

AB - A total of 72 consecutive laryngeal carcinoma patients at stage T3 or T4 were studied. The laryngeal cancer patients were treated first with concurrent chemoradiotherapy (40 Gy) in our department. Patients with residual disease subsequently underwent curative surgery, and chemoradiotherapy was continued to 70 Gy for those without residual disease. The three-year disease-specific-free survival (DSS) rates in patients with supraglottic, glottic and subglottic tumors were 58%, 71% and 100%, respectively. In patients at stage T3/T4, the DSS rates were 75%/46%, and in those with/without lymph node metastasis (N+/N-) the rates were 56%/78%. The three-year laryngeal preservation (LP) rates in patients with supraglottic/glottic/subglottic tumors, T3/T4 and N+/N- tumors were 12%/26%/50%, 28%/4% and 13%/29%, respectively. The recurrence rate was 29%, of which 75% have died, primarily of distant metastasis. These DSS and LP rates were not significantly different among the three subregions and N stages, although those in patients at stage T4 were significantly low, compared with T3 patients (p=0.01). These results suggest that additional treatment may be required for patients with T4 disease. Chemotherapy after surgery is now considered for T4 patients.

UR - http://www.scopus.com/inward/record.url?scp=84867857979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867857979&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.38.39

DO - 10.5981/jjhnc.38.39

M3 - Article

VL - 38

SP - 39

EP - 42

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 1

ER -